哌醋甲酯
心理学
注意缺陷多动障碍
临床心理学
精神科
药物警戒
注意力缺陷
发展心理学
药品
作者
Alexander Häge,Kenneth K C Man,Sarah K. Inglis,Jan K. Buitelaar,Sara Carucci,Marina Danckaerts,Regina Dittmann,Bruno Falissard,Peter Garas,Chris Hollis,Kerstin Konrad,Hanna Kovshoff,Elizabeth B. Liddle,Suzanne McCarthy,Antje Neubert,Péter Nagy,Éric Rosenthal,Edmund Sonuga‐Barke,Alessandro Zuddas,Ian C. K. Wong,David Coghill,Tobias Banaschewski
标识
DOI:10.1177/10870547241232337
摘要
Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.
科研通智能强力驱动
Strongly Powered by AbleSci AI